Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease

DM patients with CKD stages 3-4 had increased inflammatory activity compared to DM patients with normal GFR. Lipid-lowering treatment decreased the levels of MCP-1 and IFN? in DM patients with concomitant CKD, which may be beneficial with regard to the progression of both atherosclerosis and diabetic nephropathy (European Journal of Clinical Investigation)